Biology Reference
In-Depth Information
[44] Tabeta K, Hoebe K, Janssen EM, et al. The Unc93b1 mutation 3d disrupts exogenous
antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol
2006;7(2):156-64.
[45] Ewald SE, Lee BL, Lau L, et al. The ectodomain of Toll-like receptor 9 is cleaved to gen-
erate a functional receptor. Nature 2008;456(7222):658-62.
[46] Lee J, Mo JH, Katakura K, et al. Maintenance of colonic homeostasis by distinctive
apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8(12):1327-36.
[47] Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA.
Nature 2000;408(6813):740-5.
[48] Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated rec-
ognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med
2003;198(3):513-20.
[49] Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-
containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol
2007;8(5):487-96.
[50] Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug
Discovery 2006;5(6):471-84.
[51] Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides
by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.
Blood 2012;119(2):355-63.
[52] McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through
TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol
2006;311:155-78.
[53] Celhar T, Magalhaes R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes
wrong. Immunol Res 2012;53(1-3):58-77.
[54] Means TK, Latz E, Hayashi F, Muralfi MR, Golenbock DT, Luster AD. Human lupus
autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.
J Clin Invest 2005;115(2):407-17.
[55] Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced auto-
immunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol
2003;4(6):594-600.
[56] Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-
like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med
2005;202(2):321-31.
[57] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update
on Toll-like receptors. Nat Immunol 2010;11(5):373-84.
[58] Pichlmair A. Reis e Sousa C. Innate recognition of viruses. Immunity 2007;27(3):370-83.
[59] Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response
induced by double-stranded B-form DNA. Nat Immunol 2006;7(1):40-8.
[60] Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-medi-
ated type I interferon induction. Nat Immunol 2005;6(10):981-8.
[61] Rehwinkel J, Tan CP, Goubau D, et al. RIG-I detects viral genomic RNA during negative-
strand RNA virus infection. Cell 2010;140(3):397-408.
[62] Wang Y, Cella M, Gilfillan S, Colonna M. Cutting edge: polyinosinic:polycytidylic acid
boosts the generation of memory CD8 T cells through melanoma differentiation-asso-
ciated protein 5 expressed in stromal cells. J Immunol 2010;184(6):2751-5.
[63] Gitlin L, Benoit L, Song C, et al. Melanoma differentiation-associated gene 5 (MDA5)
is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS
Pathog 2010;6(1):e1000734.
[64] Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a
gene implicated in antiviral responses, protect against type 1 diabetes. Science
2009;324(5925):387-9.
[65] Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates
recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med
2006;203(8):2021-31.
[66] Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate alloresponses and
uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood
2008;112(8):3508-16.
[67] Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Mellor AL, Munn DH, Blazar BR.
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for
suppression of graft-versus-host disease (GVHD) lethality. Blood 2009;114(24):62-5070.
[68] Calcaterra C, Sfondrini L, Rossini A, et al. Critical role of TLR9 in acute graft-versus-host
disease. J Immunol 2008;181(9):6132-9.
[69] Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9 mediated immunopathology
and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host
disease. Gut 2010;59(8):1079-87.
443
Search WWH ::
Custom Search